MockV Solutions Announces Phase 1 SBIR Grant Award from the National Center for Advancing Translations Sciences

Rockville, MD – Dec. 7th, 2017 – MockV Solutions, Inc. (MockV or the Company), a
biotechnology company developing non-infectious viral clearance prediction products that
address the unmet needs of process development scientists as they establish biopharmaceutical
manufacturing platforms, announced today the receipt of a Phase I grant from the National
Center for Advancing Translations Sciences under auspices of the Small Business Innovation
Research (SBIR) program of the National Institutes of Health. The $250,000 grant under the
Award Number R43TR002231 is focused on demonstrating the utility of a non-infectious Minute
Virus of Mice-Virus Like Particle for predicting viral clearance during biopharmaceutical
process development

Mr. David Cetlin, MS, CEO of MockV said, “We are very pleased to receive this SBIR grant
from NCATS which supports the development and commercialization of our first VLP kit. This
Kit which enable scientists to predict MVM clearance on their own bench tops and will thus
allow for viral clearance screening to take place during process development and optimization,
building quality into their processes ahead of validation and regulatory filings”
About MockV Solutions Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious
viral-surrogate tools to a variety of industries that currently rely on expensive and logistically
challenging live virus analysis. MockV is developing a novel series of analytical assay kits
which will enable biopharmaceutical process development scientists to study the efficacy of
manufacturing techniques intended to remove or inactive virus, a contaminant of great concern
during the manufacturing of biopharmaceuticals. These products are only approved for clinical
or commercial use after their manufacturing processes demonstrate sufficient viral clearance.
Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and
XMuLV) in expensive and logistically challenging “spiking studies”. The lack of economical
and accurate means of analyzing viral clearance during small scale process development
increases the risk of failing viral clearance regulatory requirements – jeopardizing the timely
approval of potentially life-altering therapies. MockV’s lead product candidate, the MVM-MVP
Kit contains a non-infectious Virus like Particle (VLP) or “Mock Virus Particle” (MVP) that
mimics the physicochemical characteristics of live infectious MVM, as well as reagents and
components to quantify MVP in solution. Prototypes are available for sale.

For further information regarding MockV Solutions, Inc., please visit the Company’s website at

About this Press Release

The content is solely the responsibility of MockV Solutions, Inc. and does not necessarily
represent the official views of the National Institutes of Health.